Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHMA Chiasma	$3.76	$4.01	$2.77 ▼ $5.74	$217.68M	1.28	2.12 million shs	147 shs
DYN Dyne Therapeutics	$9.05 +1.2%	$11.69	$6.36 ▼ $47.45	$995.72M	1.08	1.82 million shs	1.99 million shs
GPCR Structure Therapeutics	$20.62 +0.9%	$23.15	$13.22 ▼ $47.48	$1.17B	-1.87	837,274 shs	372,490 shs
HROW Harrow	$31.78 +4.0%	$28.32	$20.85 ▼ $59.23	$1.16B	0.41	495,276 shs	257,698 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHMA Chiasma	0.00%	0.00%	0.00%	0.00%	0.00%
DYN Dyne Therapeutics	0.00%	-5.43%	-35.31%	+9.30%	-73.45%
GPCR Structure Therapeutics	0.00%	-2.19%	-3.96%	+36.37%	-44.94%
HROW Harrow	0.00%	+2.91%	+10.65%	+35.12%	+47.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHMA Chiasma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	3.5007 of 5 stars	4.5	3.0	0.0	0.0	2.4	2.5	0.0
GPCR Structure Therapeutics	2.9153 of 5 stars	3.5	3.0	0.0	0.0	2.8	1.7	0.6
HROW Harrow	2.6828 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHMA Chiasma	0.00	N/A	N/A	N/A
DYN Dyne Therapeutics	3.00	Buy	$41.13	354.42% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	269.40% Upside
HROW Harrow	3.00	Buy	$61.40	93.20% Upside

Current Analyst Ratings Breakdown

Latest CHMA, DYN, HROW, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHMA Chiasma	$1.11M	196.11	N/A	N/A	$1.59 per share	2.36
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
HROW Harrow	$199.61M	5.84	$0.14 per share	232.19	$1.95 per share	16.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHMA Chiasma	-$74.78M	-$1.43	N/A	N/A	N/A	N/A	-113.57%	-57.62%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	79.45	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)

Latest CHMA, DYN, HROW, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHMA Chiasma	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHMA Chiasma	N/A	7.91	7.08
DYN Dyne Therapeutics	N/A	20.35	20.35
GPCR Structure Therapeutics	N/A	23.29	23.29
HROW Harrow	2.01	0.91	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHMA Chiasma	61.68%
DYN Dyne Therapeutics	96.68%
GPCR Structure Therapeutics	91.78%
HROW Harrow	72.76%

Insider Ownership

Company	Insider Ownership
CHMA Chiasma	8.30%
DYN Dyne Therapeutics	14.14%
GPCR Structure Therapeutics	9.43%
HROW Harrow	15.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHMA Chiasma	85	57.89 million	N/A	Not Optionable
DYN Dyne Therapeutics	100	113.67 million	97.59 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable

CHMA, DYN, HROW, and GPCR Headlines

Recent News About These Companies

Are Options Traders Betting on a Big Move in Harrow Stock?

July 2, 2025 | msn.com

Harrow Earns Relative Strength Rating Upgrade

June 30, 2025 | msn.com

Harrow, Inc. (NASDAQ:HROW) Shares Bought by Westside Investment Management Inc.

June 30, 2025 | marketbeat.com

Stocks Generating Improved Relative Strength: Harrow

June 26, 2025 | msn.com

We Might See A Profit From Harrow, Inc. (NASDAQ:HROW) Soon

June 26, 2025 | finance.yahoo.com

Woodmont Investment Counsel LLC Buys 22,293 Shares of Harrow, Inc. (NASDAQ:HROW)

June 21, 2025 | marketbeat.com

Harrow Shows Market Leadership With Jump To 83 RS Rating

June 20, 2025 | msn.com

Assenagon Asset Management S.A. Sells 99,446 Shares of Harrow, Inc. (NASDAQ:HROW)

June 20, 2025 | marketbeat.com

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

June 19, 2025 | finance.yahoo.com

I Am Swimming In Dividends With +7% Yields

June 13, 2025 | seekingalpha.com

Harrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Buy" by Brokerages

June 12, 2025 | marketbeat.com

Harrow (NASDAQ:HROW) Now Covered by Analysts at BTIG Research

June 12, 2025 | marketbeat.com

What is William Blair's Estimate for Harrow Q2 Earnings?

June 12, 2025 | marketbeat.com

William Blair Initiates Coverage of Harrow (HROW) with Outperform Recommendation

June 12, 2025 | msn.com

Harrow wins new Outperform at William Blair after licensing deal for pain drug

June 10, 2025 | msn.com

Harrow (NASDAQ:HROW) Shares Gap Up - Still a Buy?

June 10, 2025 | marketbeat.com

Harrow (NASDAQ:HROW) Coverage Initiated at William Blair

June 10, 2025 | marketbeat.com

Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals

June 10, 2025 | msn.com

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 9, 2025 | prnewswire.com

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 9, 2025 | businesswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend

CHMA, DYN, HROW, and GPCR Company Descriptions

Chiasma NASDAQ:CHMA

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$9.05 +0.11 (+1.23%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$8.99 -0.06 (-0.62%)

As of 07/3/2025 04:31 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$20.62 +0.18 (+0.88%)

Closing price 07/3/2025 03:10 PM Eastern

Extended Trading

$20.62 +0.00 (+0.00%)

As of 07/3/2025 04:09 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Harrow NASDAQ:HROW

$31.78 +1.21 (+3.96%)

As of 07/3/2025 03:29 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time